• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立优化的小鼠原位膀胱癌模型。

Establishment of an optimized orthotopic bladder cancer model in mice.

机构信息

Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 85 Wujin Road, Hongkou District, Shanghai, 200080, China.

Department of Urology, Shanghai General Hospital Affiliated to Nanjing Medical University, Shanghai, 200080, China.

出版信息

BMC Urol. 2022 Sep 3;22(1):142. doi: 10.1186/s12894-022-01093-6.

DOI:10.1186/s12894-022-01093-6
PMID:36057655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9441054/
Abstract

BACKGROUND

Bladder cancer (BC) is one of the most common malignancies of the genitourinary system. Animal models offer an important tool to explore tumour initiation, progression, and therapeutic mechanisms. Our aim is to construct an optimized orthotopic BC model which is predictable, reproducible, and convenient.

METHODS

The optimized orthotopic BC model was constructed in male C57BL/6 mice utilizing microsyringes to inoculate them with a murine BC cell line (MB49). Anesthetised mice were inoculated with an MB49 cell suspension (10 µL) at approximately 5 × 10/mL. The whole process of modelling was observed and monitored every 3 days for 21 days utilizing HE staining and transabdominal ultrasonography (TUS).

RESULTS

In this study, the model showed excellent success rates for tumour formation (96.67%) and metastatic rate (89.66%). Compared to the control group (sham operation), mice in the modelling group had serous cachexia, visible haematuresis and weight loss (all P < 0.05). The lungs, liver, ureter and kidneys were found to have tumour metastasis. Moreover, the average survival time (19.73 ± 1.69 d) of modelling mice was significantly shorter than that of the control mice (P < 0.05), which remained alive.

CONCLUSION

Our study established a method using microsyringes to inject murine BC cells into the bladder wall, creating a stable transplantable BC model in mice.

摘要

背景

膀胱癌(BC)是泌尿系统最常见的恶性肿瘤之一。动物模型为探索肿瘤的发生、进展和治疗机制提供了重要工具。我们的目的是构建一种可预测、可重复且方便的优化的原位膀胱癌模型。

方法

利用微量注射器将小鼠膀胱癌细胞系(MB49)接种到雄性 C57BL/6 小鼠的膀胱壁中,构建优化的原位膀胱癌模型。麻醉小鼠以约 5×10/ml 的浓度接种 MB49 细胞悬液(10 μL)。利用苏木精和伊红(HE)染色和经腹超声(TUS)监测,观察并监测建模的全过程,21 天内每 3 天监测一次。

结果

在这项研究中,该模型的肿瘤形成率(96.67%)和转移率(89.66%)非常高。与对照组(假手术)相比,建模组小鼠出现严重的恶病质、肉眼血尿和体重减轻(均 P<0.05)。肺部、肝脏、输尿管和肾脏均发现有肿瘤转移。此外,建模小鼠的平均存活时间(19.73±1.69 d)明显短于对照组仍存活的小鼠(P<0.05)。

结论

本研究建立了一种利用微量注射器将小鼠膀胱癌细胞注射到膀胱壁中,在小鼠中建立稳定的可移植膀胱癌模型的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/df8bce803792/12894_2022_1093_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/f7165858081e/12894_2022_1093_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/52706e5e0826/12894_2022_1093_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/3f83cf281fe3/12894_2022_1093_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/58c61fa3fa21/12894_2022_1093_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/c3a6127d033b/12894_2022_1093_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/3e2fda63593e/12894_2022_1093_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/862e0e412836/12894_2022_1093_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/df8bce803792/12894_2022_1093_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/f7165858081e/12894_2022_1093_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/52706e5e0826/12894_2022_1093_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/3f83cf281fe3/12894_2022_1093_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/58c61fa3fa21/12894_2022_1093_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/c3a6127d033b/12894_2022_1093_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/3e2fda63593e/12894_2022_1093_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/862e0e412836/12894_2022_1093_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bad8/9441054/df8bce803792/12894_2022_1093_Fig8_HTML.jpg

相似文献

1
Establishment of an optimized orthotopic bladder cancer model in mice.建立优化的小鼠原位膀胱癌模型。
BMC Urol. 2022 Sep 3;22(1):142. doi: 10.1186/s12894-022-01093-6.
2
[A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer].一种建立原位MB49膀胱癌小鼠模型的简单有效方法
Nan Fang Yi Ke Da Xue Xue Bao. 2009 Apr;29(4):627-30.
3
Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer.具有类似于人类膀胱癌的高组织蛋白酶B活性的新型侵袭性原位膀胱癌模型。
J Urol. 2009 Aug;182(2):749-55. doi: 10.1016/j.juro.2009.03.076. Epub 2009 Jun 18.
4
A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.一种通过将链霉亲和素标记的生物活性白细胞介素-2固定在膀胱壁生物素化黏膜表面来治疗浅表性膀胱癌的新型免疫疗法。
Chin J Cancer. 2010 Jun;29(6):611-6. doi: 10.5732/cjc.009.10640.
5
Optimizing syngeneic orthotopic murine bladder cancer (MB49).优化同基因原位小鼠膀胱癌(MB49)。
Cancer Res. 1999 Jun 15;59(12):2834-7.
6
Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.抗白细胞介素-10R1 单克隆抗体联合卡介苗对小鼠原位肿瘤模型膀胱癌转移具有保护作用,并表现出全身特异性抗肿瘤免疫。
Clin Exp Immunol. 2014 Jul;177(1):261-8. doi: 10.1111/cei.12315.
7
[Establishment and application of an orthotopic murine bladder cancer model].[原位小鼠膀胱癌模型的建立与应用]
Ai Zheng. 2007 Apr;26(4):341-5.
8
Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model.利用前列腺特异性抗原在小鼠原位模型中测量膀胱肿瘤生长情况。
J Urol. 2004 Dec;172(6 Pt 1):2414-20. doi: 10.1097/01.ju.0000143860.50878.b1.
9
Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.用于腺病毒基因治疗的MB49小鼠膀胱癌模型的优化
Lab Anim. 2005 Oct;39(4):384-93. doi: 10.1258/002367705774286475.
10
CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.在原位膀胱癌模型中,CpG疗法优于卡介苗,并能产生CD4+ T细胞免疫。
J Immunother. 2008 Jan;31(1):34-42. doi: 10.1097/CJI.0b013e3181587d29.

引用本文的文献

1
Malevolent alliance of MYBL2 cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer.MYBL2癌干细胞与SPP1 +巨噬细胞的恶性联盟赋予膀胱癌对新辅助免疫疗法的抗性。
J Immunother Cancer. 2025 Jul 10;13(7):e011319. doi: 10.1136/jitc-2024-011319.
2
Bioprinted research models of urological malignancy.泌尿外科恶性肿瘤的生物打印研究模型
Exploration (Beijing). 2024 Feb 20;4(4):20230126. doi: 10.1002/EXP.20230126. eCollection 2024 Aug.
3
Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer.

本文引用的文献

1
Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.雌激素受体与 GATA3 在膀胱癌中的相关性:临床病理意义的系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 Oct 8;12:684140. doi: 10.3389/fendo.2021.684140. eCollection 2021.
2
How Cancer Cells Invade Bladder Epithelium and Form Tumors: The Mouse Bladder Tumor Model as a Model of Tumor Recurrence in Patients.癌细胞如何侵袭膀胱上皮并形成肿瘤:以小鼠膀胱癌模型模拟患者肿瘤复发。
Int J Mol Sci. 2021 Jun 13;22(12):6328. doi: 10.3390/ijms22126328.
3
Loss of polarity protein Par3, via transcription factor Snail, promotes bladder cancer metastasis.
晚期和转移性膀胱癌可溯源小鼠模型的建立
Cancers (Basel). 2024 Jun 17;16(12):2245. doi: 10.3390/cancers16122245.
4
Orthotopic and metastatic tumour models in preclinical cancer research.临床前癌症研究中的原位和转移瘤模型。
Pharmacol Ther. 2024 May;257:108631. doi: 10.1016/j.pharmthera.2024.108631. Epub 2024 Mar 11.
5
Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer.膀胱癌膀胱内小鼠模型中的非侵入性成像模态
Cancers (Basel). 2023 Apr 20;15(8):2381. doi: 10.3390/cancers15082381.
极性蛋白 Par3 通过转录因子 Snail 促进膀胱癌转移。
Cancer Sci. 2021 Jul;112(7):2625-2641. doi: 10.1111/cas.14920. Epub 2021 May 1.
4
The Role of Androgens and Androgen Receptor in Human Bladder Cancer.雄激素和雄激素受体在膀胱癌中的作用。
Biomolecules. 2021 Apr 18;11(4):594. doi: 10.3390/biom11040594.
5
Androgen Receptor Regulates CD44 Expression in Bladder Cancer.雄激素受体调控膀胱癌中 CD44 的表达。
Cancer Res. 2021 Jun 1;81(11):2833-2846. doi: 10.1158/0008-5472.CAN-20-3095. Epub 2021 Mar 9.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Bladder Cancer: A Review.膀胱癌:综述。
JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598.
8
Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.雌激素受体-β信号传导诱导膀胱癌顺铂耐药。
Am J Cancer Res. 2020 Aug 1;10(8):2523-2534. eCollection 2020.
9
Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities.膀胱癌:各期别及各种治疗模式下非尿路上皮变异型组织学与尿路上皮癌之比较。
Clin Genitourin Cancer. 2021 Feb;19(1):60-68.e1. doi: 10.1016/j.clgc.2020.07.011. Epub 2020 Jul 18.
10
Urobiome in Gender-Related Diversities of Bladder Cancer.尿宏基因组在膀胱癌性别相关差异中的作用。
Int J Mol Sci. 2020 Jun 24;21(12):4488. doi: 10.3390/ijms21124488.